CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) Study Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization Comparative Accuracy of Focused Cardiac Ultrasonography and Clinical Examination for Left Ventricular Dysfunction and Valvular Heart Disease: A Systematic Review and Meta-analysis The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short Utilization and programming of an automatic MRI recognition feature for cardiac rhythm management devices Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring Cholesterol-Lowering Agents Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis Short-term and long-term clinical outcomes of rotational atherectomy in resistant chronic total occlusion Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry)

Original Research

JOURNAL:CBSMD Article Link

心脏代谢临床试验中的黑洞 —— 不明原因死亡

CBSMD Keywords: cardivascular system; clinical study; trial design

Pre-reading

现代心脏代谢临床试验常将心血管死亡作为主要研究复合终点事件的一部分,由临床事件委员会(clinical event committees, CEC)明确死因。因可掌握信息不充分而无法判定死因的情况时有发生,属于临床试验终点事件的黑洞区域。 US FDA对经营管理好的临床试验的其中一项评价标准是无法明确死因的发生率应控制在罕见范围,而现实并非如此。“Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials9项心脏代谢临床试验的死亡原因进行了汇总分析,评估其中不明原因死亡(undetermined death)的发生率


同期发表在《循环》上的评论文章“Classification of Deaths in Cardiovascular Outcomes Trials”

1. 介绍了心脏代谢临床试验将死亡分为心源性死亡及非心源性死亡这一通用做法的原因;

2. 指出在使用随机、对照、设盲临床设计评估新疗法有效性和安全性的同时,虽然可能的试验偏差可通过好的试验设计得以有效的规避,但对那些已知范围外未知的把控也体现了一项优质临床试验的科研质控水平。

3. 罗列了不同试验操作系统中导致无法判定死因的数量产生变化的三种情形:
(1)    完整记录缺失或死亡判定原因不充分;
(2)    死亡过程不可知(例如独居者死亡时间不确定且未经尸检明确);
(3)    研究人员获得完整数据受限(例如随访知情同意撤回)。
4. 建议可通过加大对不明原因死亡事件的管理,进一步提高未来临床试验的数据质量,才能有效地通过试验得出心血管疗法是否确为安全或有效。